moponetug Updated Oct 29
The next major catalyst is the Phase 2 TargetTau-1 topline readout expected in 1H 2027. Positive data showing both tau biomarker clearance and cognitive benefit could validate the anti-MTBR tau approach and trigger milestone payments from BMS, while negative or mixed results would severely impair Prothena's pipeline value given the recent PRX019 termination. Watch for BMS's Q4 2026 earnings commentary for any trial timing updates.
- Moponetug targets tau pathology, a distinct mechanism from approved amyloid-clearing Alzheimer's drugs (Leqembi, Kisunlea), offering a potential combination or second-line approach in a massive market.
- FDA Fast Track designation (October 2025) provides regulatory pathway advantages including rolling review and priority review eligibility.
- BMS, a top-tier pharma partner, is fully funding development and has already paid $135 million in licensing fees, with up to $562.5 million in remaining milestones plus tiered royalties.
- No tau-targeting antibody has been approved for Alzheimer's to date; the biology is unproven and several prior anti-tau antibodies have failed in clinical trials.
- The Phase 2 readout is still 6-8 months away (1H 2027), and the stock could drift lower with no near-term catalysts.
- BMS recently terminated the PRX019 collaboration (October 28, 2026), removing up to $617.5 million in potential milestones and raising questions about BMS's commitment to the neuroscience partnership.